Kramer H J, Lichardus B
Klin Wochenschr. 1986 Aug 15;64(16):719-31. doi: 10.1007/BF01734338.
Twenty-five years after the discoveries of the existence of atrial granules and of volume receptors in the heart atria the search for natriuretic hormones has led to the isolation and identification of the atrial natriuretic factors (ANF) now considered as a hormonal system. These peptides are probably synthesized and stored in the Golgi apparatus of cardiac myocytes and are released in response to atrial wall stretch following acute plasma volume expansion and increased central blood volume, e.g., during head-out water immersion, in arterial hypertension, or increased left and/or right atrial pressure in cardiac failure, but also possibly in response to increased frequency of myocardial contractions, e.g. in paroxysmal tachycardia. The mechanisms of the renal action of these potent natriuretic hormones are not yet precisely known. Increased GFR may contribute to the initial rise in urinary sodium excretion and increased renal medullary blood flow to the later phase of natriuresis. The proximal tubule, the thin descending and the ascending limb of Henle's loop and especially the medullary collecting tubule were so far incriminated as tubular sites of action of ANF. Finally, recycling of sodium in medullary tissue and secretion of sodium via back-flux from the interstitium into the medullary collecting tubule are postulated to result in the hypernatric urine observed after ANF administration. Direct suppression of the secretion of renin, aldosterone, vasopressin, and vasopressin-stimulated cAMP synthesis may also contribute to its diuretic, natriuretic, and antihypertensive effects. The renal hemodynamic and tubular as well as the adrenal and systemic vascular effects are related to enhanced cGMP synthesis in medium-sized arterial vessels, in glomeruli and specific tubular segments, and in adrenal tissue, and may be calcium dependent. Specific ANF-binding sites were detected in these target organs. Although increased ANF release was observed in response to atrial distension in various disease states, which may contribute to renal sodium elimination in human hypertension and congestive heart failure, further studies are needed to identify its precise physiological and pathophysiological significance.
在发现心房颗粒及心房中的容量感受器存在25年后,对利钠激素的研究已导致心房利钠因子(ANF)的分离和鉴定,现在它被视为一种激素系统。这些肽可能在心肌细胞的高尔基体中合成并储存,并在急性血容量扩张和中心血容量增加后,如头低位浸浴时、动脉高血压时或心力衰竭时左和/或右心房压力升高时,因心房壁牵张而释放,但也可能在心肌收缩频率增加时,如阵发性心动过速时释放。这些强效利钠激素的肾脏作用机制尚未完全明确。肾小球滤过率增加可能有助于尿钠排泄的初始增加,而肾髓质血流增加则有助于利尿后期的作用。到目前为止,近端小管、亨氏袢的细降支和升支,尤其是髓质集合管被认为是ANF的肾小管作用部位。最后,推测髓质组织中钠的再循环以及钠通过从间质反流到髓质集合管的分泌导致了ANF给药后观察到的高钠尿。直接抑制肾素、醛固酮、血管加压素的分泌以及血管加压素刺激的cAMP合成也可能有助于其利尿、利钠和降压作用。肾脏血流动力学和肾小管以及肾上腺和全身血管的作用与中等大小动脉血管、肾小球和特定肾小管节段以及肾上腺组织中cGMP合成增加有关,并且可能依赖于钙。在这些靶器官中检测到了特异性ANF结合位点。尽管在各种疾病状态下,心房扩张时观察到ANF释放增加,这可能有助于人类高血压和充血性心力衰竭时肾钠的排泄,但仍需要进一步研究以确定其确切的生理和病理生理意义。